"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at gefitinib for people with advanced non small cell lung cancer (1839IL/0709)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared
Advanced non small cell lung cancer can be difficult to treat. When this trial was done, earlier research showed that gefitinib could be a useful treatment for this group of patients. Gefitinib is a type of biological therapy called a tyrosine kinase inhibitor.
The aim of this trial was to see how well gefitinib works for people with advanced non small cell lung cancer. And to find out more about the side effects.
Summary of results
The trial team found that gefitinib and best supportive care was no better than best supportive care alone for people with advanced non small cell lung cancer.
1,688 people took part in this trial
- Two thirds had best supportive care and gefitinib
- One third had best supportive care and a dummy drug (
The researchers analysed the results in 2005. They looked at both groups to see how long people lived. They found no difference between the people who had gefitinib and the people who had the dummy drug.
The main side effects of gefitinib were mild and included skin rashes and diarrhoea.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Nick Thatcher